|摘要||目的 研究罗格列酮对非酒精性脂肪肝(NAFL)的作用,并探讨胰岛素抵抗(IR)与NAFL的关系.方法 以喂食高脂饲料建立大鼠NAFL模型,将其随机分为罗格列酮治疗组和模型对照组,治疗4周后处死动物,观察肝脏组织学变化,并测定肝功能、FBG、FIns、血脂、瘦素、脂联素等指标.结果 罗格列酮组与模型对照组相比,肝脂肪变性明显好转,肝功能明显改善,丙氨酸氨基转移酶为54±19 U/L与101±24 U/L,门冬氨酸氨基转移酶为151±37 U/L与198±48 U/L,碱性磷酸酶为87±16 U/L与115±39 U/L(P＜0.01);脂联素水平显著上升,瘦素水平明显减低;胰岛素抵抗指数(HOMA-IR)明显减低,分别为6.9±1.8和12.0±1.2(P＜0.01);血清TG、TC、LDL-C水平显著降低(P＜0.01).结论 IR在NAFL的发生发展过程中可能发挥重要作用,罗格列酮可有效逆转动物模型的NAFL.
Objective To investigate the effect of rosiglitazone on non-alcoholic fatty liver (NA and to explore the relationship between insulin resistance and NAFL. Methods Animal model of NAFL was established by feeding Sprague-Dawley rats a high-fat diet for 8 weeks. The model rats were then randomized into rosiglitazone-treated and untreated groups. The animals were sacrificed after being treated with rosiglitazone or vehicle for 4 weeks. The histological changes of liver were examined, and liver function, fasting plasma glucose, fasting serum insulin, serum lipid profile, leptin, and adiponectin were measured. Results As compared with untreated group, hepatic steatosis and liver function were significantly improved in rosiglitazone-treated group. Alanine aminotransferase (ALT) was 54±19 U/L vs 101±24 U/L, aspartic acid aminotransferase (AST) 151±37 U/L vs 198±48 U/L, and alkaline phosphatase (ALP) 87±16 U/L vs 115±39 U/L, respectively (P<0.01). Serum adiponectin level was higher, and serum leptin level and insulin resistance index (HOMA-IR) were lower in rosiglitazone-treated group than in untreated group. HOMA-IR was 6.9±1.8 vs 12.0±1.2 (P<0.01). Serum triglyceride, total cholesterol and low density lipoprotein-cholesterol level were significantly decreased in rosiglitazone-treated group as compared with untreated group (P<0.01). Conclusions Insulin resistance might play important role in the pathogenesis of NAFL. Rosiglitazone effectively reverses NAFL in animal model.|